#USA #San Francisco #Tasman Therapeutics #R-107 #Osmind

Tasman Therapeutics and Osmind Join Forces

Tasman Therapeutics, a clinical-stage biopharmaceutical firm, announced a significant multi-year strategic partnership with Osmind, renowned for its innovative use of technology and real-world evidence in psychiatry. This collaboration is set to bolster Tasman's R-107 Ketamine program, which is aimed at offering new hope to patients suffering from treatment-resistant depression (TRD).

Background of the Partnership

The partnership will primarily support Tasman's pivotal Phase 3 ROCKET program while also laying the foundation for a distinctive commercialization strategy for R-107. Aimed at revolutionizing how depression is treated, R-107 is an investigational oral extended-release ketamine pill designed for administration at home, thus making treatment more accessible for patients with difficult-to-treat depressive disorders.

Osmind, which operates the largest network of independent psychiatric practices in the U.S., is well-poised to enhance the R-107 program through its extensive clinical network and innovative approach to mental health treatment. The company utilizes a sophisticated electronic health record and artificial intelligence platform that has created the largest real-world dataset concerning rapid-acting psychopharmacologic substances. As a result, this positions Osmind as a premier collaborator for firms developing new treatments in the psychiatric field.

Strategic Implementation

In the short term, Tasman will leverage Osmind’s vast resources and data network to enhance the ROCKET Phase 3 study's design and implementation. This will include optimizing trial structures, characterizing safety protocols, and formulating regulatory strategies. Additionally, Osmind will assist in identifying clinical trial sites across its national network of psychiatric practices, ensuring widespread awareness and efficient execution.

Looking to the future, the strategic partnership is set to enhance commercialization capabilities for R-107. Osmind’s technological infrastructure, combined with its data-driven approach, promises improved patient care and compliance strategies. Notably, the commercialization initiative aims to include longitudinal evidence generation and an innovative consumer-facing patient application that could redefine how care is delivered.

Insights from Executive Leadership

Dan Browne, CEO of Tasman Therapeutics, expressed optimism about the partnership, stating, “As we progress through Phase 3 and approach what could be the first and only oral, at-home monotherapy for TRD, Osmind's data and technological prowess give us a substantial advantage in both trial execution and safe large-scale patient delivery.”

Jimmy Qian, Co-founder and President of Osmind, echoed this sentiment, highlighting the importance of creating an effective, safe, and accessible treatment option for depression. “We're excited to leverage our achievements and technologies to assist Tasman as they progress through their final trial stages, aiming to alter how depression treatment is experienced by patients,” he remarked.

About R-107

R-107 is a cutting-edge oral ketamine product currently in its Phase 3 clinical trial stage, being explored as a standalone treatment for individuals with TRD. Clinical studies conducted in Australia and New Zealand have demonstrated R-107's rapid onset and capacity for lasting improvement in TRD symptoms compared to placebo, indicating promising results.

The ROCKET program aims to release topline data by 2027. Tasman Therapeutics, which operates out of San Francisco, is committed to developing novel solutions for neuropsychiatric disorders. With an experienced leadership team at the helm, Tasman has set out to bring first-in-class treatments to the market.

Conclusion

The partnership between Tasman Therapeutics and Osmind marks a significant milestone in psychiatric treatment development. By combining Tasman's innovative drug R-107 with Osmind's data-centric model and extensive network, the collaborative effort aims to pave the way for better treatment options for people struggling with persistent depression. This partnership illustrates the potential of combining technology and clinical expertise to provide more efficient and effective mental health care.

For more information, visit Tasman Therapeutics and Osmind.